HBF

Tilia Homes and Hopkins Homes announce 'Zero Bills' partnership with Octopus Energy

Retrieved on: 
Tuesday, April 2, 2024
Octopus Energy, Partnership, Tilia Homes, Save, Watt, HBF, Carbon, Terra firma, NHBC, Housing, Heart, Home Builders Federation, Octopus, Tilia, Renewable energy

SOLIHULL, England, April 2, 2024 /PRNewswire/ -- Tilia Homes and Hopkins Homes have today announced they have joined Octopus Energy's 'Zero Bills' proposition on an exclusive number of properties.

Key Points: 
  • SOLIHULL, England, April 2, 2024 /PRNewswire/ -- Tilia Homes and Hopkins Homes have today announced they have joined Octopus Energy's 'Zero Bills' proposition on an exclusive number of properties.
  • Simon Gabbitas, Group ESG Director for Tilia Homes and Hopkins Homes, said: "As the cost-of-living crisis continues to bite, we are delighted to join forces with Octopus Energy to offer drastically reduced home running costs for our customers.
  • "At Tilia Homes and Hopkins Homes, we are committed to reducing carbon emissions and exploring new ways to incorporate cutting-edge technology, materials, and designs into our developments to boost energy efficiency.
  • With our 'Zero Bills' smart proposition, Tilia Homes and Hopkins Homes homeowners can enjoy not only energy bill-free homes, but also a genuine shift towards sustainable living.

Tilia Homes and Hopkins Homes announce 'Zero Bills' partnership with Octopus Energy

Retrieved on: 
Tuesday, April 2, 2024
Octopus Energy, Partnership, Tilia Homes, Save, Watt, HBF, Carbon, Terra firma, NHBC, Housing, Heart, Home Builders Federation, Octopus, Tilia, Renewable energy

SOLIHULL, England, April 2, 2024 /PRNewswire/ -- Tilia Homes and Hopkins Homes have today announced they have joined Octopus Energy's 'Zero Bills' proposition on an exclusive number of properties.

Key Points: 
  • SOLIHULL, England, April 2, 2024 /PRNewswire/ -- Tilia Homes and Hopkins Homes have today announced they have joined Octopus Energy's 'Zero Bills' proposition on an exclusive number of properties.
  • Simon Gabbitas, Group ESG Director for Tilia Homes and Hopkins Homes, said: "As the cost-of-living crisis continues to bite, we are delighted to join forces with Octopus Energy to offer drastically reduced home running costs for our customers.
  • "At Tilia Homes and Hopkins Homes, we are committed to reducing carbon emissions and exploring new ways to incorporate cutting-edge technology, materials, and designs into our developments to boost energy efficiency.
  • With our 'Zero Bills' smart proposition, Tilia Homes and Hopkins Homes homeowners can enjoy not only energy bill-free homes, but also a genuine shift towards sustainable living.

MHI Group Presents "Best Innovation 2023" Awards for Activities that Contribute to Protecting the Environment

Retrieved on: 
Wednesday, February 21, 2024
Hydrogen, Filtration, Energy, Toxicity, Tokyo Institute of Technology, LCC, Noto Peninsula, Tremor, CCUS, Engineering, Innovation Center station, LPG, PTFE, Polytetrafluoroethylene, Transport, Engineering Division, Mitsubishi Heavy Industries, Pressure, MHI, HBF, Dioxin, Kyoto University, Carbon, Chemical engineering, Incineration, Taisei Corporation, CO2, Knowledge, Primetals Technologies, Temperature, Logistics, Works, LNG, Government, GTCC, BOG, Renewable energy

Through this in-house program, the Company aims to raise environmental awareness and encourage further innovation among its groupwide employees.

Key Points: 
  • Through this in-house program, the Company aims to raise environmental awareness and encourage further innovation among its groupwide employees.
  • An anchorless construction method enables easy equipment installation and layout changes-, a feature that has brought accolades from multi-tenant warehouse owners.
  • By utilizing knowledge and expertise of MHI group, a "liquefied CO2 handling system" enabling transport of liquefied CO2 in large volumes is being developed.
  • In these ways, MHI Group has been making its initiatives toward realizing a carbon neutral society widely known.

MiNA Therapeutics Presents New Data for its HbF Program at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference

Retrieved on: 
Wednesday, January 24, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Patient, Liposome, Therapy, RNAa, Keystone, MST, RNA, Mina, Fetal hemoglobin, Conference, Bone marrow, Sickle cell disease, Safety, HBF, Vivo, HBG, Pharmaceutical industry

MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, announced today that it will present new pre-clinical data for its lead RNA activation program targeting fetal hemoglobin (HbF) at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference in Banff, Alberta, Canada.

Key Points: 
  • MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, announced today that it will present new pre-clinical data for its lead RNA activation program targeting fetal hemoglobin (HbF) at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference in Banff, Alberta, Canada.
  • The data will be presented on January 24, 2024, at 7:30 pm MST during a poster presentation.
  • MiNA’s HbF program is designed to increase transcription of the gamma globin (HBG) gene, enabling patients with beta-hemoglobinopathies to produce enhanced levels of HbF.
  • MiNA anticipates advancing its HbF program, the first program to emerge from its genetic medicine portfolio, into pre-clinical development in 2024.

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Retrieved on: 
Monday, January 8, 2024
SCD, LNP, Liver, Beam Therapeutics, Pfizer, Conference, Genotype, Sickle cell disease, Gene editing, Second wave, Survival, ESCAPE, Biotechnology, IND, Research, AAT, Pizzicato, Mortality, G6PC, Therapy, Third wave, Clinical trial, Glucose, DSM-IV codes, GMP, Trial of the century, AATD, Transplant, Growth, Investment, Hematology, Stem cell, HBF, Safety, Liver disease, Piz, CTA, Genetic distance, Beam

CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported progress across the company’s hematology and genetic disease portfolios and provided updates on anticipated upcoming milestones.

Key Points: 
  • “Our vision is to establish Beam as a sustainable, fully integrated company pioneering a new class of genetic medicines with base editing.
  • Preclinical models suggest base editing could lead to improved HbF induction and lower residual disease-causing hemoglobin S compared to existing gene therapy options.
  • The company is on-track to report initial data on multiple patients from the BEACON trial in the second half of 2024.
  • Beam expects to report an initial clinical dataset for BEAM-201 in the second half of 2024.

Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Retrieved on: 
Tuesday, January 2, 2024
SCD, Medical Subject Headings, Marketing, Febrile neutropenia, European Commission, Sickle cell disease, INN, Limited, Hematology, Physician, ATC, EMA, B cell, International, ATMP, HLA, Vomiting, Headache, Thalassemia, Nausea, Tissue, Disease, Civil service commission, HSC, CD34, Cas9, Haematopoiesis, Vertex Pharmaceuticals, Public, Gene, Transplant, Medication package insert, Volatile organic compound, Committee, Patient, Liver disease, TDT, HBF, Mouth ulcer, Cell, Anatomy, Medicine, Hemoglobinopathy, BCL11A, Health, CHMP

Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Key Points: 


Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Retrieved on: 
Monday, December 18, 2023
Medicine, Vomiting, B cell, Anatomy, ATC, Gene, Sickle cell disease, European Commission, Health, International, Transplant, HSC, Headache, INN, Thalassemia, Tissue, Vertex Pharmaceuticals, Liver disease, Disease, Febrile neutropenia, EMA, Civil service commission, Patient, Medication package insert, HBF, Hemoglobinopathy, Limited, CHMP, Mouth ulcer, Marketing, Committee, Advanced Therapy Medicinal Product, HLA, Medical Subject Headings, ATMP, Cas9, Nausea, TDT, BCL11A, Hematology, Volatile organic compound, Public, SCD, Physician, Cell, CD34, Haematopoiesis, Instrumentation, Vaccine, Veterinary medicine, Dentistry, Dietary supplement, Pharmaceutical industry, Medicinal plants, Anemia

Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Key Points: 


Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

Retrieved on: 
Friday, December 8, 2023
Malignancy, VOC, DNA, Sickle cell disease, Abdominal pain, Headache, Patient, Research, Hemoglobin A, Cas9, CRISPR, Oxygen, Volatile organic compound, Recurrence, Fever, Mutation, Priority review, DSM-IV codes, Vomiting, Bone marrow, Hematology, China Biologic Products, Safety, Food, Multimedia, Rejection, HBF, Ronas Voe, Health, Person, Nausea, Throat, Mouth, Hispanic and Latino Americans, Public, Adolescence, Stomatitis, Risk, Tissue, Febrile neutropenia, History, End organ damage, Fetal hemoglobin, Animal, Pain, SCD, B cell, Regenerative medicine, Heated tobacco product, Disease, FDA, African Americans, Mouth ulcer, Vaccine, Cosmetics, Blood, Human services, Dietary supplement, Freedom, Pharmaceutical industry

Sickle cell disease is a group of inherited blood disorders affecting approximately 100,000 people in the U.S.

Key Points: 
  • Sickle cell disease is a group of inherited blood disorders affecting approximately 100,000 people in the U.S.
  • The primary problem in sickle cell disease is a mutation in hemoglobin, a protein found in red blood cells that delivers oxygen to the body's tissues.
  • Casgevy, a cell-based gene therapy, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises.
  • In patients with sickle cell disease, increased levels of HbF prevent the sickling of red blood cells.

Revolutionary Satellite Communication Antenna Offers Unprecedented Flexibility for Military Applications

Retrieved on: 
Thursday, November 30, 2023
VSAT, HBF, AESA, GEO, PESA, DBF, ESA, Beamforming, MEO, United States patent law, LEO, Communication, Passive electronically scanned array, Environment, Patent, Pathfinder, Drive Away/Shiawase no Jōken, Military personnel, Government, Communications satellite, Cable television, Array

Traditionally, satellite ground terminals have been designed to operate in a dedicated fashion on a specific communication satellite or network.

Key Points: 
  • Traditionally, satellite ground terminals have been designed to operate in a dedicated fashion on a specific communication satellite or network.
  • The phased array antenna is utilized as the feed for the parabolic reflector when operating on a GEO satellite and as a standalone antenna when operating on a LEO or MEO satellite.
  • This configuration also allows MONDO to function concurrently as a traditional parabolic antenna on a GEO satellite and as a traditional ESA on a LEO/MEO satellite.
  • PathFinder intends to license this innovative antenna design to antenna manufacturers," said Roger McGarrahan, CEO of PathFinder Digital.

FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease

Retrieved on: 
Tuesday, August 22, 2023
Fulcrum, Communication, HBF, SCD, PRC2, Investigational New Drug, Patient, Sickle cell disease, Anti-transglutaminase antibodies, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Pharmaceutical industry, Agency

“We are pleased with the FDA’s decision to lift the clinical hold and are eager to advance FTX-6058 through clinical development to address the significant unmet need in the sickle cell disease community,” said Alex C. Sapir, Fulcrum’s president and chief executive officer.

Key Points: 
  • “We are pleased with the FDA’s decision to lift the clinical hold and are eager to advance FTX-6058 through clinical development to address the significant unmet need in the sickle cell disease community,” said Alex C. Sapir, Fulcrum’s president and chief executive officer.
  • We look forward to building on these results with plans to resume enrollment for patients with SCD.”
    On February 23, 2023, the FDA placed the IND for FTX-6058 on clinical hold.
  • In its communication, the Agency noted preclinical data previously submitted in April, October and December 2022, and non-clinical and clinical evidence of hematological malignancies observed with other inhibitors of polycomb repressive complex 2 (PRC2).
  • In connection with the clinical hold, Fulcrum suspended dosing in the Phase 1b trial of FTX-6058 and worked diligently with the Agency to resolve the hold.